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Background/Introduction
Trimodality therapy has frequently been applied to
patients with locally advanced esophageal cancer. How-
ever, to preoperatively predict the response to neoadju-
vant therapy and prognosis is difficult.
Aims/Objectives
The present study aimed to determine the diagnostic
applicability of 18F-fluorodeoxyglucose-positron emis-
sion tomography/computed tomography (FDG-PET/CT)
to evaluating the response and prognosis after trimodal-
ity therapy for esophageal squamous cell carcinoma
(ESCC).
Method
The responses of 111 patients with ESCC who under-
went neoadjuvant chemoradiotherapy (nCRT) followed
by surgery were monitored by measuring the maximal
standardized uptake value (SUVmax) of the primary
tumor on FDG-PET before and after nCRT. Associa-
tions between SUVmax and pathological response of
primary tumor and prognosis were analyzed.
Results
We compared the SUVmax between good (Japan Eso-
phageal Society response evaluation criteria grades 3/2;
n = 87, 78.4 %) and poor (grade 1; n = 24, 21.6 %)
responders. The SUVmax after nCRT (post-SUVmax) in
good and poor responders were 2.7 ± 0.9 and 4.4 ± 2.2,
respectively (p < 0.0001). The rates of the SUVmax
decrease after nCRT (ΔSUVmax) in these patients sig-
nificantly differed (71 ± 14% vs. 60 ± 21%, respectively,
p = 0.003). The area under receiver operating character-
istic curves (AUC) showed that the optimal cut-off for
post-SUVmax and ΔSUVmax were 3.7 (AUC, 0.76; 95%
CI, 0.63-0.89; P < 0.001) and 70% (AUC, 0.65; 95% CI,
0.52-0.78; P = 0.02) for predicting good responder,
respectively, and that the patients could be separated
into groups with and without good response using these
cut-off values. The 5-year overall survival rate was sig-
nificantly higher for patients with ΔSUVmax > 70% than
≥ 70 % (66% vs. 42%, p = 0.04), and multivariable analy-
sis including preoperative factors also revealed ΔSUV-
max (≥ 70/> 70%) as an independent prognostic factor
for disease-specific survival (OR, 2.22; 95%CI, 1.02 -
4.76; p = 0.04).
Discussion/Conclusion
Post-SUVmax and ΔSUVmax were valuable preoperative
factors for predicting tumor response and survival in
patients with ESCC after trimodality therapy. Thus,
FDG-PET/CT findings are useful for tailoring optimal
therapies for individual patients with ESCC.
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